維替泊芬作用機制 - Medchemexpress - MCE中國.docx 免費下載
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領(lǐng)
文檔簡介
1、Product Data SheetVerteporfinCat. No.: HY-B0146CAS No.: 129497-78-5分式: CHNO分量: 718.79作靶點: YAP; Apoptosis; Autophagy作通路: Stem Cell/Wnt; Apoptosis; Autophagy儲存式: 4C, protect from light* In solvent : -80C, 6 months; -20C, 1 month (protect from light)溶解性數(shù)據(jù)體外實驗 DMF : 25 mg/mL (34.78 mM; Need ultrasonic)D
2、MSO : 8 mg/mL (11.13 mM; Need ultrasonic)H2O : 0.1 mg/mL (insoluble)SolventMass1 mg 5 mg 10 mgConcentration制備儲備液1 mM 1.3912 mL 6.9561 mL 13.9123 mL5 mM 0.2782 mL 1.3912 mL 2.7825 mL10 mM 0.1391 mL 0.6956 mL 1.3912 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;旦配成溶液,請分裝保存,避免反復凍融造成的產(chǎn)品失效。儲備液的保存式和期限:-80C, 6 months; -20
3、C, 1 month (protect from light)。-80C 儲存時,請在 6 個內(nèi)使,-20C 儲存時,請在 1 個內(nèi)使。體內(nèi)實驗請根據(jù)您的實驗動物和給藥式選擇適當?shù)娜芙獍?。以下溶解案都請先按?In Vitro 式配制澄清的儲備液,再依次添加助溶劑:為保證實驗結(jié)果的可靠性,澄 的儲備液可以根據(jù)儲存條件,適當保存;體內(nèi)實驗的作液,建議您現(xiàn)現(xiàn)配,當天使; 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的式助溶1. 請依序添加每種溶劑: 10% DMF 40% PEG300 5% Tween-80 45% saline2
4、.Solubility: 2.5 mg/mL (3.48 mM); Clear solution請依序添加每種溶劑: 10% DMF 90% (20% SBE-CD in saline)3.Solubility: 2.5 mg/mL (3.48 mM); Suspended solution; Need ultrasonic請依序添加每種溶劑: 10% DMF 90% corn oil4.Solubility: 2.5 mg/mL (3.48 mM); Clear solution; Need ultrasonic請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-
5、80 45% salineSolubility: 0.8 mg/mL (1.11 mM); Clear solution此案可獲得 0.8 mg/mL (1.11 mM,飽和度未知) 的澄清溶液。以 1 mL 作液為例,取 100 L 8.0 mg/mL 的澄 DMSO 儲備液加到 400 L PEG300 中,混合均勻;向上述體系中加Page 1 of 2 www.MedChemE50 L Tween-80,混合均勻;然后繼續(xù)加 450 L 理鹽定容 1 mL。5. 請依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 0.8 m
6、g/mL (1.11 mM); Suspended solution; Need ultrasonic and warming此案可獲得 0.8 mg/mL (1.11 mM) 的均勻懸濁液,懸濁液可于服和腹腔注射。以 1 mL 作液為例,取 100 L 8.0 mg/mL 的澄 DMSO 儲備液加到 900 L 20% 的 SBE-CD 理鹽溶液中,混合均勻。BIOLOGICAL ACTIVITY物活性 Verteporfin (CL 318952) 種于光動療法的光敏劑,于消除與年齡相關(guān)的 斑變性等疾病相關(guān)的眼內(nèi)異常管 。 Verteporfin 種 YAP 抑制劑,可破壞 YAP-TEA
7、D 相互作。Verteporfin 可以誘導細胞噬 (apoptosis)。 Verteporfin 種噬 (autophagy) 抑制劑,通過抑制噬體形成,在早期阻斷噬。IC & Target IC50: YAP-TEAD interaction體外研究 Verteporfin is specifically selected by PDX-cell screening. The concentrations to cause 50% growth inhibition (GI50) forPhLO, PhLH, and PhLK are 228 nM, 395 nM, and 538 nM
8、, respectively, whereas GI50 for ALL-1, TCC-Y/sr, and NPhA1are 3.93 M, 2.11 M, and 5.61 M, respectively. GSH significantly reduces the sensitivity of 2 out of 3 PDX cells toverteporfin. Verteporfin reduces the mitochondrial membrane potential in PDX cells1. Verteporfin reduces the PTX-resistance on
9、HCT-8/T cells by inhibiting YAP expression and combination therapy with verteporfin and NSC 125973shows synergism on inhibition of YAP and cytotoxicity to HCT-8/T2.體內(nèi)研究 Verteporfin (10 mg/kg, c.s.c.) and BMS-354825 significantly reduces the leukemia cell ratio, and combined therapyfurther reduced th
10、e number of leukemia cells in the spleen1.PROTOCOLCell Assay 1 PDX cells co-cultured with S17 cells are treated with 16 combinations of verteporfin (60 nM, 120 nM, 180 nM, and240 nM) and BMS-354825 (12 nM, 24 nM, 36 nM, and 48 nM). The viabilities of cells treated with each combinationare measured a
11、fter 48 h using FACS Aria flow cytometer. In order to estimate drug interaction between verteporfinand BMS-354825, a normalized isobologram and fraction affectedcombination index (CI) plot are made usingCompuSyn software. CI values greater than 1.0 indicated antagonistic effects, equal to 1.0 additi
12、ve effects, and below1.0 synergistic effects.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice: PhLO cells (1.0107/mouse) are injected intravenously into 6-week-old male NOG mice, which are then treatedAdministration 1 with vehicle, verteporfi
13、n (140 mg/kg/day), BMS-354825 (20 mg/kg/day), and a combination of these drugs from days22 to 28. Verteporfin is administered by continuous subcutaneous infusion (c.s.c.) using Alzet osmotic pumps. Anintraperitoneal injection (i.p.) is performed for BMS-354825. All mice are sacrificed on day 28 and
14、the chimerism ofleukemia cells is investigated by flow cytometer using an anti-human CD19 antibody and antimouse CD45 antibody.Blood concentrations of verteporfin are calculated by LCMS-2020.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻Pag
15、e 2 of 3 www.MedChemE Cancer Cell. 2019 Sep 16;36(3):302-318.e7. Cell Res. 2020 Mar;30(3):229-243. Hepatology. 2019 Sep 11. Mol Cell. 2019 Jan 3;73(1):7-21.e7. Sci Adv. 2020 May 22.See more customer validations on HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Morishita T, et al. The photosensitize
16、r verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia andsynergistically works with BMS-354825. Oncotarget. 2016 Aug 2.2. Pan W, et al. Verteporfin can Reverse the NSC 125973 Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation throughInhibiting YAP Expression. Cell Physiol Biochem. 2016;39(2):481-90.3. Donohue E, et al. The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine ina pancreatic ductal adenocarcinoma model.J
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
- 6. 下載文件中如有侵權(quán)或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年度個人貴金屬交易融資合同范本民間版4篇
- 二零二五年度網(wǎng)絡(luò)安全股份公司成立股東數(shù)據(jù)安全協(xié)議3篇
- 2025版危險品運輸駕駛員勞動合同標準范本3篇
- 2025年高標準圍墻建設(shè)及維護服務合同細則3篇
- 二零二五年酒類企業(yè)產(chǎn)品追溯與防偽技術(shù)合作合同3篇
- 2024破樁勞務分包合同
- 2025年食堂承包合同補充協(xié)議強調(diào)食品安全與衛(wèi)生規(guī)范3篇
- 與物業(yè)公司合同范本(2024版)
- 鄭州科技學院《藝術(shù)考察與創(chuàng)新設(shè)計》2023-2024學年第一學期期末試卷
- 2025年度戶外景觀門窗工程分包合同范本8篇
- 南通市2025屆高三第一次調(diào)研測試(一模)地理試卷(含答案 )
- 2025年上海市閔行區(qū)中考數(shù)學一模試卷
- 2025中國人民保險集團校園招聘高頻重點提升(共500題)附帶答案詳解
- 勞務派遣招標文件范本
- 信息安全意識培訓課件
- Python試題庫(附參考答案)
- 碳排放管理員 (碳排放核查員) 理論知識考核要素細目表三級
- 2024年河北省中考數(shù)學試題(含答案解析)
- 小學二年級數(shù)學口算練習題1000道
- 納布啡在產(chǎn)科及分娩鎮(zhèn)痛的應用
- DZ/T 0462.4-2023 礦產(chǎn)資源“三率”指標要求 第4部分:銅等12種有色金屬礦產(chǎn)(正式版)
評論
0/150
提交評論